Transforming Medical Technology: The Launch of the Innovative Devices Access Pathway in the UK

By HEOR Staff Writer

September 20, 2023

A New Era of Medical Innovation

The Department of Health and Social Care (DHSC), Health Technology Wales (HTW), the Medicines and Healthcare products Regulatory Agency (MHRA), and several other health organizations have launched the Innovative Devices Access Pathway (IDAP) pilot. This new pathway, backed by £10 million of government funding, aims to fast-track patient access to innovative technologies by providing comprehensive support and advice to innovators and manufacturers.

A Pathway Paved with Potential

The IDAP is more than just a funding program. It’s a vision for the future of healthcare in the UK. The pathway aims to support the rapid development of innovative technologies that can be introduced into the National Health Service (NHS) to address unmet clinical needs. This is not just about getting new products to market quickly, but also ensuring they meet the highest standards of safety, quality, and effectiveness.

The pilot phase of the IDAP has now been launched, with innovators invited to submit Expressions of Interest for access into the pathway. Successful applicants will receive a range of support, including the development of a targeted product roadmap, system navigation advice, and support with Health Technology Assessments (HTA) for product realization and adoption.

The IDAP is open to both commercial and non-commercial innovators of medical technology in the UK and abroad. The submissions for the pilot phase opened on 19 September 2023 and will close on 29 October 2023. The future of healthcare is here, and it’s innovative, inclusive, and incredibly exciting.

Reference url

Recent Posts

Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Combatting Antimicrobi...

By João L. Carapinha

December 12, 2025

Provisional Deal Ushers in EU Pharmaceutical Reform The European Parliament and Council have reached a provisional agreement to overhaul the EU's pharmaceutical policy framework, marking a major step in the EU Pharmaceutical Refor...
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicines Lifecycle

By HEOR Staff Writer

December 9, 2025

In the pharmaceutical industry, AI governance in pharmaceuticals is crucial for harnessing artificial intelligence's potential in drug discovery, clinical trials, and patient monitoring. How can pharma companies integrate AI ethically across the medicines lifecycle? This article draws on a recent...
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced Patient Care

By HEOR Staff Writer

December 8, 2025

Digital cardiac rehabilitation is transforming how patients with cardiovascular disease access vital recovery support, and if you're wondering about the latest NICE recommendations for digital platforms in cardiac rehab, here's the key update. NICE has conditionally approved seven innovative tool...